ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.75 CNY | +3.97% |
|
+6.62% | +14.18% |
| Apr. 29 | Zhejiang Huahai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 24 | Huahai Pharmaceutical Gets Approval to Market Busulfan Injection | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 22,824 | 49,180 | 32,246 | 32,429 | 21,592 | 24,653 | - | - |
| Enterprise Value (EV) 1 | 24,627 | 51,018 | 32,246 | 37,867 | 27,214 | 27,189 | 26,966 | 24,653 |
| P/E ratio | 38.4 x | 52.8 x | 63.7 x | 27.3 x | 25.7 x | 20.7 x | 17.2 x | - |
| Yield | 1.16% | 0.59% | 0.46% | 1.1% | 1.36% | 0.96% | 1.63% | 1.31% |
| Capitalization / Revenue | 4.24 x | 7.58 x | 4.85 x | 3.92 x | 2.6 x | 2.51 x | 2.19 x | - |
| EV / Revenue | 4.57 x | 7.87 x | 4.85 x | 4.58 x | 3.28 x | 2.76 x | 2.39 x | - |
| EV / EBITDA | 19.9 x | 29 x | - | 17.2 x | 14.4 x | 10.7 x | 9.07 x | - |
| EV / FCF | - | 163,961,201 x | - | - | - | - | - | - |
| FCF Yield | - | 0% | - | - | - | - | - | - |
| Price to Book | 4.07 x | 7.84 x | 5.11 x | 4.44 x | 2.78 x | 2.68 x | 2.4 x | - |
| Nbr of stocks (in thousands) | 1,454,610 | 1,454,608 | 1,488,714 | 1,483,475 | 1,471,850 | 1,471,850 | - | - |
| Reference price 2 | 15.69 | 33.81 | 21.66 | 21.86 | 14.67 | 16.75 | 16.75 | 16.75 |
| Announcement Date | 4/30/20 | 4/8/21 | 4/18/22 | 4/17/23 | 4/16/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 5,388 | 6,485 | 6,644 | 8,266 | 8,309 | 9,838 | 11,280 | - |
| EBITDA 1 | 1,237 | 1,760 | - | 2,207 | 1,896 | 2,552 | 2,971 | - |
| EBIT 1 | 824.4 | 1,287 | 868.4 | 1,547 | 1,125 | 1,599 | 1,923 | - |
| Operating Margin | 15.3% | 19.84% | 13.07% | 18.72% | 13.53% | 16.25% | 17.05% | - |
| Earnings before Tax (EBT) 1 | 760.9 | 1,215 | 786.9 | 1,509 | 1,100 | 1,484 | 1,787 | - |
| Net income 1 | 569.6 | 929.8 | 487.5 | 1,168 | 830.5 | 1,175 | 1,417 | - |
| Net margin | 10.57% | 14.34% | 7.34% | 14.13% | 10% | 11.95% | 12.56% | - |
| EPS 2 | 0.4091 | 0.6400 | 0.3400 | 0.8000 | 0.5700 | 0.8100 | 0.9750 | - |
| Free Cash Flow | - | 311.2 | - | - | - | - | - | - |
| FCF margin | - | 4.8% | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | 17.68% | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | 33.46% | - | - | - | - | - | - |
| Dividend per Share 2 | 0.1818 | 0.2000 | 0.1000 | 0.2400 | 0.2000 | 0.1600 | 0.2733 | 0.2200 |
| Announcement Date | 4/30/20 | 4/8/21 | 4/18/22 | 4/17/23 | 4/16/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales | 1,773 | 2,051 | 2,014 | 2,428 | 2,059 | 2,235 | 1,913 | - | 2,499 | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT | 200.8 | 499.9 | 329.7 | 516.8 | 243.6 | 450.5 | 230.3 | - | 374.6 | - | - | - |
| Operating Margin | 11.33% | 24.38% | 16.36% | 21.29% | 11.83% | 20.15% | 12.04% | - | 14.99% | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 1 | 0.1000 | 0.2900 | 0.1600 | 0.2500 | 0.1200 | 0.2700 | 0.1100 | 0.0700 | 0.1900 | 0.2500 | 0.2200 | 0.1800 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 4/25/22 | 8/30/22 | 10/29/22 | 4/17/23 | 4/28/23 | 8/30/23 | 10/31/23 | 4/16/24 | 4/29/24 | - | - | - |
1CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | 1,803 | 1,838 | - | 5,439 | 5,622 | 2,535 | 2,312 |
| Net Cash position 1 | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 1.458 x | 1.044 x | - | 2.465 x | 2.966 x | 0.9936 x | 0.7781 x |
| Free Cash Flow | - | 311 | - | - | - | - | - |
| ROE (net income / shareholders' equity) | 12.2% | 15.6% | 7.43% | 16.6% | 10.6% | 13.7% | 14.8% |
| ROA (Net income/ Total Assets) | - | 7.84% | - | 6.95% | - | 5.6% | 6.6% |
| Assets 1 | - | 11,860 | - | 16,810 | - | 20,986 | 21,463 |
| Book Value Per Share 2 | 3.860 | 4.310 | 4.240 | 4.930 | 5.290 | 6.250 | 6.980 |
| Cash Flow per Share 2 | 1.210 | 1.070 | 0.6300 | 0.8400 | 1.500 | 1.330 | 1.450 |
| Capex 1 | 790 | 1,244 | - | 2,306 | 1,588 | 1,798 | 1,748 |
| Capex / Sales | 14.66% | 19.19% | - | 27.89% | 19.11% | 18.28% | 15.5% |
| Announcement Date | 4/30/20 | 4/8/21 | 4/18/22 | 4/17/23 | 4/16/24 | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
16.75
CNY
Average target price
16.37
CNY
Spread / Average Target
-2.29%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +14.18% | 3.28B | |
| +33.13% | 664B | |
| +29.29% | 567B | |
| -7.35% | 354B | |
| +18.73% | 330B | |
| +4.63% | 286B | |
| +13.79% | 234B | |
| +4.93% | 199B | |
| -9.78% | 196B | |
| -4.90% | 148B |
- Stock Market
- Equities
- 600521 Stock
- Financials Zhejiang Huahai Pharmaceutical Co., Ltd.
